Robert A. Winn, MD, president of the Association of American Cancer Institutes (AACI) and director of VCU Massey Comprehensive Cancer Center, has appointed two community advocates to the steering committee of his AACI presidential initiative, Inclusive Excellence.
DNA fragments circulating in patients’ blood can reveal the presence of tumors long before CT scans and lead to more agile use of cancer drugs.
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced grants awarded for developing innovative investigator-initiated research involving the medication relugolix.
The Association of American Cancer Institutes (AACI) supports President Biden’s nomination of W. Kimryn Rathmell, MD, PhD, MMHC, as the next director of the National Cancer Institute (NCI).
Akshu Balwan, MD, breathes easier these days because The University of New Mexico Comprehensive Cancer Center launched a new comprehensive lung cancer screening clinic as part of the institution's lung cancer screening program.
Patients with advanced prostate cancer with tumors harboring RB1 gene loss or neuroendocrine features often have a poor prognosis and limited treatment options.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
A phase 1 clinical trial conducted exclusively at Roswell Park Comprehensive Cancer Center shows that a novel treatment regimen can make immunotherapy more effective in patients with metastatic triple-negative breast cancer (mTNBC).
The James P. Allison Institute at MD Anderson hosted its inaugural scientific symposium on Nov. 10, bringing together more than 400 leading scientists in immunotherapy and immunobiology.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
The biennial prize recognizes a new generation of leaders in cancer research
Howard Meyers, of Dallas, Texas, a member of The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), has committed $25 million to The University of Texas MD Anderson Cancer Center to establish the Meyers Institute for Oncology Nursing.
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates the most advanced computational and data science approaches with the institution’s extensive scientific and clinical expertise to significantly improve patient’s lives by transforming cancer care and research.
Elevating the combined strengths of the nationally recognized cancer center and the state’s largest academic health system will revolutionize care in New Jersey and beyond.
New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that breast cancer patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy.
The Association of American Cancer Institutes (AACI) congratulates Monica Bertagnolli, MD, on her U.S. Senate confirmation today as the next director of the National Institutes of Health (NIH).
The morning of Sunday Oct. 29th wasn’t too different for Albuquerque resident Nicholas Juskiewicz and Brandon Behrens, MD, a trauma surgeon at The University of New Mexico Hospital. Jusckiewicz put on his cycling kit and headed to Albuquerque’s Old Town area to start the Day of the Tread 61-mile bicycle ride.
MD Anderson and Jazz Pharmaceuticals announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz’s investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
As more cancer care is delivered in outpatient treatment centers such as Fred Hutchinson Cancer Center in Seattle, the burden on cancer caregivers is evolving. Fred Hutch has developed a package of stories to support and celebrate the role of caregivers in cancer care.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational, and clinical cancer research from MD Anderson experts. irectly into the liver for patients with metastatic uveal melanoma.
For Gladys Tsao-Wu, MD, and Jennifer Chan, MD, reconstruction is as much about helping patients recover emotionally as it is about physical restoration. For over a decade, the two surgeons have been a team, helping breast cancer survivors in New Mexico.
SEATTLE — November 2, 2023 — Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. November is Lung Cancer Awareness Month. If you’re looking for resources, see our media tip sheet and contact [email protected] to set up interviews.
Using nanoparticles administered directly into the cerebrospinal fluid (CSF), a research team has developed a treatment that may overcome significant challenges in treating a particularly deadly brain cancer.
Craig D. Blinderman, MD, has been appointed Chief of the Supportive Care Service at Memorial Sloan Kettering Cancer Center (MSK).
Domestic violence went down or stayed the same during the first 10 months of the COVID-19 pandemic in five major U.S. cities. However, domestic violence involving firearms increased in three of those cities, according to a new UC Davis study published in the Journal of Family Violence.
National Comprehensive Cancer Network publishes free NCCN Guidelines for Patients with information on improving well-being and reducing suffering and distress for people with cancer; available at NCCN.org/patientguidelines.
The Cancer Research Institute is proudly awarding Dr. Ananda Goldrath with the 2023 Fredrick W. Alt award for New Discoveries in Immunology.
Cancer center scientists have identified a combination of biological effects that likely make some people with HIV vulnerable to cancer
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include positive results from a Phase I trial for patients with TP53-mutant acute myeloid leukemia, a novel machine learning platform to identify cancer biomarkers from liquid biopsies, a tumor-specific multi-microRNA delivery system to improve treatment outcomes in glioblastoma, a combination strategy to overcome treatment resistance in KRAS-mutated pancreatic cancer, and a new target for improving treatment response in patients with stomach cancer that has metastasized to the peritoneal cavity.
A study by UC Davis Health endocrinology researchers shows a high prevalence of thyroid cancer among transgender female veterans, the first evidence of such a disparity.
In order to grow and train future clinical and translational scientists, The University of Kansas Cancer Center has received a $2.4 million grant from the National Cancer Institute (NCI).
As Lung Cancer Awareness Month begins in November, experts at Fred Hutchinson Cancer Center remain committed to advancing early screening, helping people quit smoking and developing new ways to detect and treat lung cancer.
A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.
Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors
Perioperative immunotherapy plus neoadjuvant chemotherapy significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC) compared to chemotherapy alone. Results from the Phase III CheckMate 77T study were presented today at the 2023 European Society of Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in maintenance setting, according to researchers from The University of Texas MD Anderson Cancer Center.
This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
A UC Davis study shows the first-in-human imaging of the body’s CD8 T cell immune response to COVID-19 infection in recovering patients.
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to enhance responses to immunotherapy in glioblastoma, potentially opening the door for wider use of engineered messenger RNA (mRNA) for cancer therapy. The study was published today in Nature Communications.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy, suggesting that lactic acid-producing bacteria present in various cancers may serve as novel therapeutic targets. The study, published today in Cancer Cell, reported that a particular bacterial species, Lactobacillus iners (L. iners), caused cancer cells to respond to radiation by rewiring metabolic signaling pathways to resist treatment. The researchers also found that L. iners was associated with poorer clinical outcomes in patients with cervical cancer.
In a town hall, health and health science leaders from The University of New Mexico and around the state provided answers for Sen. Ben Ray Luján, (D) New Mexico, regarding the causes and possible solutions to New Mexico’s challenges in growing and maintaining a vibrant health care workforce. They shared on ways to enhance federal partnerships that could help, including bringing more resources to New Mexico to serve as an incubator for new innovations.
Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain.
Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, October 20 to 24. The annual meeting brings together clinicians, researchers, and patient advocates from all over the world. At ESMO 2023, oncologists will discuss new data and report updates on ongoing studies.
Ludwig Cancer Research announces its launch of the Ludwig Leadership Fellows Program, which aims to accelerate the careers of exceptional young scientists by helping them establish genuinely independent programs of research immediately after the completion of their graduate studies.
SEATTLE – OCTOBER 17, 2023 – Fred Hutchinson Cancer Center has announced the recipients of the 2023 Dr. Eddie Méndez Scholar Award, which recognizes early-career underrepresented minority scientists and scientists with disabilities.
In a new study published in Cell Chemical Biology, Moffitt Cancer Center researchers demonstrate this, showing that the ROS1 inhibitor lorlatinib has activity against an additional protein called PYK2. The team also reveals the mechanisms of this inhibition.
Daniel Herranz Benito, PhD, PharmD, resident researcher at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center and assistant professor of pharmacology at Rutgers Robert Wood Johnson Medical School, has received $800,000 from the V Foundation for Cancer Research, a premier cancer research charity, to support his research on acute lymphoblastic leukemia (ALL).
The Kraft Family Blood Donor Center, which provides lifesaving blood products to patients at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, announced today that it has finished implementing a more inclusive blood donation process, in alignment with updated guidelines issued by the U.S. Food and Drug Administration (FDA) that will allow many gay and bisexual men to donate blood and platelets.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
